MML Investors Services LLC Sells 296,838 Shares of Pfizer Inc. (NYSE:PFE)

MML Investors Services LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 21.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,090,300 shares of the biopharmaceutical company’s stock after selling 296,838 shares during the period. MML Investors Services LLC’s holdings in Pfizer were worth $28,926,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in the company. MetLife Investment Management LLC lifted its stake in Pfizer by 1.8% in the fourth quarter. MetLife Investment Management LLC now owns 1,500,026 shares of the biopharmaceutical company’s stock valued at $39,796,000 after purchasing an additional 26,451 shares during the last quarter. Natixis increased its position in shares of Pfizer by 190.7% in the fourth quarter. Natixis now owns 5,276,396 shares of the biopharmaceutical company’s stock worth $139,983,000 after purchasing an additional 3,461,074 shares during the last quarter. Norinchukin Bank The increased its stake in Pfizer by 9.1% in the fourth quarter. Norinchukin Bank The now owns 254,397 shares of the biopharmaceutical company’s stock valued at $6,749,000 after acquiring an additional 21,283 shares during the last quarter. Ossiam lifted its position in Pfizer by 44.2% in the 4th quarter. Ossiam now owns 265,695 shares of the biopharmaceutical company’s stock worth $7,049,000 after buying an additional 81,496 shares during the last quarter. Finally, Capital International Inc. CA grew its position in Pfizer by 10.6% during the fourth quarter. Capital International Inc. CA now owns 349,653 shares of the biopharmaceutical company’s stock valued at $9,276,000 after acquiring an additional 33,489 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group dropped their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research report on Tuesday, April 8th. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.07.

Pfizer Stock Up 0.4 %

Shares of PFE opened at $22.13 on Monday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $125.50 billion, a PE ratio of 15.69, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The business’s 50 day moving average is $24.88 and its 200 day moving average is $26.15.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 earnings per share. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.